Breathe Well Live Well
|
Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist …
MarketWatch (press release) These include demonstration that AZD1419 is capable of producing long lasting disease-modifying effects in a mouse model of atopic asthma. Under the terms of the amended 2006 research collaboration and license agreement, AstraZeneca will provide to … |
View full post on asthma – Google News
 Proactive Investors USA & Canada |
AstraZeneca Pays Dynavax $3M to Speed Up Start of Asthma Drug Trials
Genetic Engineering News Dynavax Technologies will receive a $3 million payment from AstraZeneca to fund the initiation of clinical trials with their partnered asthma drug AZD 1419. The payment comes as part of the firms' amended collaboration to accelerate the start of … AstraZeneca, Dynavax amend agreement to accelerate development of asthma drug Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for Asthma Dynavax Technologies Corporation partners with AstraZeneca to advance AZD 1419 … |
View full post on asthma – Google News
Proactive Investors USA & Canada |
AstraZeneca, Dynavax amend agreement to accelerate development of asthma drug
Proactive Investors USA & Canada AstraZeneca (NYSE:AZN) and Dynavax Technologies (NASDAQ:DVAX) announced Wednesday they have amended their collaboration agreement so as to accelerate the development of AZD1419, intended for the treatment of asthma. Under the terms of the agreement, … Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for Asthma Dynavax gets $3M in reworked asthma deal with AstraZeneca |
View full post on asthma – Google News
|
Dynavax gets $3M in reworked asthma deal with AstraZeneca
Bizjournals.com (blog) Dynavax Technologies Corp. will receive $3 million upfront after the Berkeley drug developer and pharmaceutical giant AstraZeneca amended a deal to accelerate a trial on a experimental asthma treatment. Dynavax (NASDAQ: DVAX) will manage the early … Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for Asthma |
View full post on asthma – Google News
|
Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for Asthma
MarketWatch (press release) If AstraZeneca chooses to advance the program following completion of Phase 2a, Dynavax will receive a $20 million milestone payment, and AstraZeneca will retain its rights to develop the candidate therapy and to commercialize the resulting asthma … |
View full post on asthma – Google News
|
AstraZeneca withdraws asthma drug
Manchester Evening News Drugs giant AstraZeneca is ending production of a pressurised metered dose inhaler version of its asthma treatment Pulmicort, which has been developed with technology partner SkyePharma. Cheshire-based AstraZeneca said that 'complex manufacturing … Astra pulls asthma product, hitting SkyePharma AZ withdraws asthma drug, bad news for SkyePharma SkyePharma crashes |
View full post on asthma – Google News
|
US Court Upholds Injunction Protecting AstraZeneca Asthma Drug
NASDAQ LN) asthma drug Pulmicort Respules. The US Court of Appeals for the Federal Circuit upheld the injunction on a 2-1 vote. A federal trial judge in New Jersey … |
View full post on asthma – Google News
|
Astrazeneca Wins Dismissal of Verus's Lawsuit Over Children's Asthma Drug
Bloomberg The London-based drugmaker agreed in 2007 to pay more than $310 million to Verus for its pediatric asthma-medicines program. Under the deal, Verus got $30 … |
View full post on asthma – Google News